When should ICD‑10 code C50.812 and Z17.1 be used for a patient with an active left‑breast malignant neoplasm and a prior breast‑cancer history?

ICD-10 Code Usage for C50.812 and Z17.1

ICD-10 code C50.812 should be used to designate a malignant neoplasm of the overlapping sites of the left female breast, while Z17.1 should be used to indicate estrogen receptor positive status when this biomarker information is clinically relevant and documented. These codes are applied during active treatment and follow-up of breast cancer patients.

Code C50.812: Malignant Neoplasm of Overlapping Sites of Left Female Breast

• C50.812 specifically identifies a primary breast malignancy involving overlapping or multiple sites within the left breast 1, 2
• This code is appropriate when the tumor cannot be classified to a single specific anatomic subsite of the breast (such as upper outer quadrant, lower inner quadrant, etc.) 1
• The code should be used for active malignancy during initial diagnosis, treatment phases, and documented recurrence 3
• For patients with a history of breast cancer who are disease-free, a different code (Z85.3 for personal history of malignant neoplasm of breast) would be more appropriate rather than continuing to use C50.812 4

Code Z17.1: Estrogen Receptor Positive Status

• Z17.1 documents estrogen receptor (ER) positive status, which is a critical biomarker for treatment decisions 2, 3
• This code should be used when ER status has been confirmed by immunohistochemistry on core needle biopsy or surgical specimen 5, 2
• ER status should be assessed using standardized methodology (e.g., Allred score or H-score) and is considered positive when present 2
• Biomarker status including ER should be re-evaluated in metastatic lesions whenever possible, as discordance between primary and metastatic tumors can occur and may affect treatment selection 3

Clinical Context for Code Application

Active Disease Scenarios

• During initial diagnosis and treatment of left breast cancer with documented ER-positive status, both codes are appropriate 1, 2
• For locally recurrent disease in the left breast, C50.812 remains appropriate if the recurrence involves overlapping sites 3
• In metastatic breast cancer, C50.812 may still be used to document the primary site, though additional codes for metastatic sites would be required 3

Prior History Considerations

• If the patient has completed treatment and is disease-free, the personal history code (Z85.3) should replace C50.812 4
• Z17.1 may continue to be relevant even in disease-free patients if ER status impacts ongoing endocrine therapy decisions or surveillance strategies 6, 7
• For patients on adjuvant endocrine therapy for ER-positive disease, Z17.1 remains clinically relevant documentation 1, 5

Common Pitfalls to Avoid

• Do not use C50.812 for patients with only a history of breast cancer who are currently disease-free—this misrepresents active disease status 4
• Avoid using outdated biomarker information—if metastatic disease develops, re-biopsy and re-code based on current tumor biology when feasible 3
• Do not assume ER status remains unchanged—approximately 20% of cases show discordance in receptor status between primary and recurrent/metastatic disease 3
• Ensure proper documentation timing—biomarker codes like Z17.1 should reflect the most recent pathological assessment, particularly if obtained from metastatic sites 2, 3

Documentation Requirements

• Core needle biopsy or surgical specimen pathology must confirm both the malignancy and ER status before coding 5, 2
• At least 2-3 tissue cores should be obtained for adequate assessment 2
• Multifocal or multicentric tumors require biopsy of all lesions to ensure accurate coding 2
• Clip or carbon marking of biopsied sites facilitates accurate surgical resection and pathological correlation 2